Mepron — Competitive Intelligence Brief

Mepron (ATOVAQUONE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial [EPC]. Area: Immunology.

marketed Antimalarial [EPC] ATP-binding cassette sub-family G member 2 Immunology Small molecule

Target snapshot

Mepron (ATOVAQUONE). Mepron works by inhibiting the electron transport chain in the mitochondria of Plasmodium parasites, ultimately leading to their death.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Mepron TARGET	ATOVAQUONE		marketed	Antimalarial [EPC]	ATP-binding cassette sub-family G member 2	1992-01-01
Cresemba	ISAVUCONAZONIUM	Astellas Pharma	marketed	Azole Antifungal	ATP-binding cassette sub-family G member 2	2015-01-01
Mycamine	MICAFUNGIN	Teva Pharms Usa Inc	marketed	Echinocandin Antifungal	ATP-binding cassette sub-family G member 2	2005-01-01
Cancidas	CASPOFUNGIN	Merck & Co.	marketed	Echinocandin Antifungal	ATP-binding cassette sub-family G member 2	2001-01-01
Protonix	pantoprazole	Generic (originally Byk Gulden/Altana/Nycomed)	marketed	Proton pump inhibitor (PPI)	ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1	2000-02-02
Kaletra	LOPINAVIR	Abbvie Deutschland Gmbh Co. Kg	marketed	Cytochrome P450 3A Inhibitor [EPC]	ATP-binding cassette sub-family G member 2	2000-01-01
Nogitecan	topotecan	Novartis	marketed	topotecan	ATP-binding cassette sub-family G member 2	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial [EPC] class)

1. · 2 drugs in this class
2. GSK · 1 drug in this class
3. Novartis · 1 drug in this class
4. State University of New York - Upstate Medical University · 1 drug in this class